Stay updated with breaking news from Independent Data. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
.jpg)
A glance at some of the day's highlights from the Proactive Investors US and Canada newswires
The final interim analysis, involving 800 completed patients, will be submitted to DSMB for review and recommendations on whether to...
Abstract While it is now widely accepted that host inflammatory responses contribute to lung injury, the pathways that drive severity and distinguish coronavirus disease 2019 (COVID-19) from other viral lung diseases remain poorly characterized. We analyzed plasma samples from 471 hospitalized patients recruited through the prospective multicenter ISARIC4C study and 39 outpatients with mild disease, enabling extensive characterization of responses across a full spectrum of COVID-19 severity. Progressive elevation of levels of numerous inflammatory cytokines and chemokines (including IL-6, CXC...
With Recent Advancements, North America Is Expected To Dominate Psychedelic Drugs Market Financialnewsmedia.com News Commentary Share this article Share this article PALM BEACH, Fla., March 9, 2021 /PRNewswire/ -- The time of "Tune In… Turn On… and Dropout" psychedelics, such as certain, mushrooms and of course, LSD were not only not legal, but no researcher could even suggest studying the compounds… they were universally declared taboo. My, but how times have changed now that the baby boomers are old and want treatments for what life is bringing them now… new, effective treatments. ...
05 February 2020 Syncona Ltd, a leading healthcare company focused on founding, building and funding a portfolio of global leaders in life science, notes the announcement that its portfolio company, Achilles Therapeutics, a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that an Independent Data and Safety Monitoring Committee (IDSMC) has completed its first review of the ongoing, first-in-human Phase I/II CHIRON and THETIS trials and has recommended that both clinical trials continue as planned. The fu...